Nesiritide

Therapeutic

Treatment of acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion

Structural features

SMILES

CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO

Sequence

SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH

Molar mass

3464.07 g/mol

Constitutional members:

32

Natural amino acids

32

D-Amino acids

0

N-terminus

H

C-terminus

COOH

Cyclic

yes

Members/cycle

17

Bond to form cycle

side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

IV

Terminal half-life

18 min

Protein binding

-

Absorption and Bioavailability

As a peptide, nesiritide has poor bioavailability and therefore is only available for intravenous administration.

References